Eli Lilly and Company $LLY is Kornitzer Capital Management Inc. KS's 3rd Largest Position

Key Points

• Kornitzer Capital Management Inc. KS reduced its position in Eli Lilly by 10% in Q4 to 111,140 shares (valued at $119.44M), making LLY its 3rd largest holding and about 2.5% of the fund's portfolio.
• Eli Lilly posted a Q1 blowout—revenue up 55.5% YoY and EPS of $8.55 versus $6.97 expected—raised FY2026 guidance, saw Mounjaro capture roughly 60% of the GLP‑1 market, and drew multiple analyst target upgrades.
• Offsetting positives, FDA reports tying Lilly’s Foundayo to liver‑failure cases have triggered a near‑term selloff and introduce elevated regulatory and PR risk despite analysts treating the incidents as largely isolated.

Kornitzer Capital Management Inc. KS lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 111,140 shares of the company's stock after selling 12,388 shares during the period. Eli Lilly and Company comprises about 2.5% of Kornitzer Capital Management Inc. KS's holdings, making the stock its 3rd largest holding. Kornitzer Capital Management Inc. KS's holdings in Eli Lilly and Company were worth $119,440,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Brighton Jones LLC lifted its stake in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Schnieders Capital Management LLC. lifted its stake in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock worth $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company during the second quarter worth about $356,000. Finally, Nebula Research & Development LLC bought a new stake in Eli Lilly and Company during the second quarter worth about $749,000. Institutional investors own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 outperformance and raised guidance — Lilly reported a blowout quarter (revenue +55% YoY, EPS well ahead of estimates) and lifted full‑year guidance, supporting the bull case for continued GLP‑1 growth. LLY Q1 Deep Dive
• Positive Sentiment: Mounjaro dominance — Reports highlight Lilly capturing roughly 60% of the GLP‑1 market and Mounjaro revenue surging, reinforcing market share and pricing power in obesity/diabetes treatments. Eli Lilly Captures 60% of the GLP‑1 Market
• Positive Sentiment: Wall Street backing — Multiple firms boosted targets and ratings (Barclays to $1,400; Wolfe reaffirmed outperform with $1,325 target; Cantor Fitzgerald and others raised views), which can sustain buying pressure. Barclays Adjusts Eli Lilly Price Target
• Positive Sentiment: Shareholder returns — Board declared a $1.73 quarterly dividend, adding incremental income support for investors. Lilly Declares Second‑Quarter 2026 Dividend
• Neutral Sentiment: Valuation/conviction pieces — Several outlets argue the pullback has made LLY's valuation more attractive (Fool, 24/7 Wall St.), offering differing price targets and buy arguments for long‑term investors. Is Eli Lilly Stock Heading for $1,000?
• Positive Sentiment: High‑profile endorsements — Media/hosts (including Jim Cramer) have publicly praised Lilly’s weight‑loss franchise and Foundayo, which can attract retail/institutional interest. Eli Lilly’s Weight Loss Pill is Better Than Novo’s, Says Jim Cramer
• Negative Sentiment: Foundayo safety signal — FDA records of liver‑failure cases tied to Foundayo prompted a near‑term selloff and caution from some investors; analysts largely view the reports as isolated but the item increases regulatory & PR risk. FDA Reports Liver Failure in Patient Taking Lilly's Foundayo

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on LLY shares. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a research note on Friday. Royal Bank Of Canada started coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $1,250.00 target price for the company. Scotiabank reissued an "outperform" rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Rothschild & Co Redburn boosted their target price on Eli Lilly and Company from $875.00 to $880.00 and gave the company a "neutral" rating in a research note on Friday, April 10th. Finally, Weiss Ratings reissued a "buy (b)" rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,217.59.

Eli Lilly and Company Trading Up 0.4%

LLY opened at $967.49 on Tuesday. The business has a 50 day simple moving average of $947.05 and a two-hundred day simple moving average of $987.36. The firm has a market capitalization of $914.11 billion, a price-to-earnings ratio of 34.37, a PEG ratio of 1.13 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 33.79 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.